Cannara Biotech Inc. reported earnings results for the third quarter and nine months ended May 31, 2023. For the third quarter, the company reported sales was CAD 0.896054 million compared to CAD 0.827187 million a year ago. Revenue was CAD 15.94 million compared to CAD 10.06 million a year ago. Net income was CAD 2.93 million compared to CAD 1.43 million a year ago. Basic earnings per share from continuing operations was CAD 0.03 compared to CAD 0.01 a year ago. Diluted earnings per share from continuing operations was CAD 0.03 compared to CAD 0.01 a year ago.
For the nine months, sales was CAD 2.66 million compared to CAD 2.55 million a year ago. Revenue was CAD 39.28 million compared to CAD 24.05 million a year ago. Net income was CAD 2.31 million compared to net loss of CAD 0.248025 million a year ago. Basic earnings per share from continuing operations was CAD 0.03 compared to basic loss per share from continuing operations of CAD 0.01 a year ago. Diluted earnings per share from continuing operations was CAD 0.03 compared to diluted loss per share from continuing operations of CAD 0.01 a year ago.